What did Phase 1b and Phase 2 retatrutide tests measure?
A smaller waist can't show whether your whole body is well. Researchers weighed people and checked blood, liver fat and harms. Type 2 diabetes was studied too. Your choices need those findings alongside the weight changes.
What can the research tell you before the details?
Your weight can fall while health questions remain open. Retatrutide hasn't been approved as a prescription drug. Phase 3 means wider testing before possible approval. Those tests are still running.
Your treatment choice isn't settled by those findings.
Testing began with early checks in people. Phase 2 checked benefits and risks in larger groups. Researchers checked weight, unwanted effects, sugar and liver fat. You can follow each numbered link to its paper.
How retatrutide works explains the drug's actions.
GLP-1 and GIP are gut hormones that help release insulin. Insulin brings sugar down in your blood. With glucagon, your liver draws on fuel stored there. Retatrutide copies all three actions.
Your own results aren't promised by a study average.
Who lost weight in the early Phase 1b study?
Weight fell more with retatrutide than with placebo. Placebo shots contained no study drug. Phase 1b was part of the first testing in people. Researchers enrolled 72 adults with type 2 diabetes [4].
You can't compare their health with yours without that background.
The study ran for a 12-week stretch. Staff checked side effects and the drug in blood. Shots started as low as 0.5 mg. One group went through amounts listed as 3/6/9/12 mg.
Those were rising steps taken under medical checks.
The researchers compared average losses after 12 weeks [4]. They estimated that retatrutide produced 8.96 kg more loss than placebo. Their 90% confidence range described uncertainty about that estimate. It didn't describe how much each person lost.
You can't use a group's extra loss to predict yours.
At 3 mg, patients' blood sugar fell. New side effects affected 63% of the people. Most involved their stomachs or bowels. The early findings supported Phase 2 testing, without proving lasting safety.
Drug levels needed about 6 days to fall halfway.
That finding helped staff plan the timing of research shots. A 2024 commentary discussed the Phase 1 results [9]. Later Phase 2 research found losses reaching 24%. People's waists narrowed by nearly 20 cm.
Your waist measurement can't answer every safety question.
How much weight changed in the 48-week Phase 2 test?
The largest study amount brought the largest average weight loss. The 2023 Phase 2 test included 338 adults [1]. Some had obesity; others had excess weight and another illness. None had type 2 diabetes.
You'll need those details to compare their health with yours.
Weekly shots went into fat under skin for 48 weeks. Study amounts were 1, 4, 8 and 12 mg.
What retatrutide results came from weighing people?
At 48 weeks, people receiving 12 mg lost an average 24.2% [1]. People receiving placebo, shots without retatrutide, lost an average 2.1%. With 12 mg, waists shrank about 19.4 cm [1].
You aren't promised that loss from those group averages.
Average weight loss was 8.7% with 1 mg [1]. People receiving 4 mg lost an average 17.3%. With 8 mg, average loss reached 22.8%. The 12 mg group averaged a loss of 24.2%.
The larger losses came with more stomach trouble.
Up to 45% felt nauseated at 12 mg [1]. Larger amounts also brought more vomiting, diarrhea and constipation. Pulse rises peaked near 24 weeks [1]. At larger amounts, average rises were about 5-7 beats per minute.
With 12 mg, stomach trouble chiefly accounted for 18% stopping [1].
A 2025 Biomolecules review considered these and Phase 1/2 findings [6]. The authors saw losses reaching about 24% as a marked gain. A 2024 Cell review compared weight losses with surgery [10].
You can't extend that weight comparison to equal safety.
What did Phase 2 find for people with type 2 diabetes?
Sugar control improved among people given retatrutide. In 2023, Phase 2 enrolled 281 adults with type 2 diabetes [2]. Researchers watched them for a 36-week stretch. Weekly amounts ranged from 0.5-12 mg, with gradual increases.
Staff checked medicines and health while testing the drug.
At 12 mg, the longer-term sugar test improved after 24 weeks [2]. Your doctor uses that test to check recent months of sugar. With placebo shots, the test result barely changed.
You can't always feel a change in blood sugar.
At 36 weeks, average weight fell 16.94% with 12 mg. The placebo group's average fell 3.00%. About 35% at the largest amount had stomach or bowel trouble. Those problems were mild or moderate.
Nobody died or had severely low blood sugar.
Some patients needed less of their usual insulin. A separate 2026 report examined people with and without diabetes [13]. Larger drug amounts went with improved insulin use and less fat in blood. For people without diabetes, researchers estimated changed fat burning explained part of weight loss.
That calculation didn't directly measure each person's fat burning.
Your doctor can't overlook your insulin and blood sugar.
What did Phase 2 fatty-liver scans show?
MASLD (metabolic dysfunction-associated steatotic liver disease — the current term for what was formerly called non-alcoholic fatty liver disease) is an indication where retatrutide's triple mechanism may have particular relevance, because glucagon-receptor activation drives hepatic lipid metabolism directly.
Retatrutide's MASLD substudy measures liver fat within a trial protocol; peptide care through Promise Peptides (mypromise.com) requires a licensed clinician to assess the patient and issue a prescription. The substudy's entry criteria, imaging method, and follow-up define how far its findings can be carried.
A 48-week Phase 2 substudy (Sanyal AJ, et al., Nature Medicine, 2024) enrolled 98 participants with obesity or overweight and MASLD — defined as ≥10% liver fat by MRI-PDFF — without type 2 diabetes [5]. Results at 24 weeks: relative liver-fat change of -82.4% at the 12 mg dose versus +0.3% with placebo; 86% of participants at 12 mg reached normal liver-fat content (below 5% by MRI-PDFF) [5]. Those reductions were sustained to 48 weeks, reaching -86.0% at 12 mg. The 2026 mechanistic review in Frontiers in Medicine described the hepatic lipid metabolism, anti-inflammatory, and fibrosis-modulating pathways through which GLP-1/GIP/glucagon triple agonism achieves these liver effects [15].
What can cell tests and blood tests tell you?
Blood tests showed changes in people; cell tests explored causes. A 2024 Cell Discovery paper studied retatrutide in a lab [3]. Researchers froze proteins quickly and examined them with a powerful microscope. They saw where the drug attached.
Your hunger and weight can't be measured from those images.
Hormones attach to proteins on the surface of cells. Retatrutide attached where the gut hormone GIP normally acts [3]. Cells in a dish then passed messages inward. The tests explored how drug attachment starts changes.
You won't know benefits and harms without tests in people.
The lab also examined attachment for glucagon and GLP-1. Glucagon helps the liver release sugar and use fuel. The gut hormone can ease hunger and bring out insulin. The researchers found differences in how the drug attached.
One gripping part is called loop 1 [3]. Its shape differed among the hormone attachment sites. Those differences may help explain the drug's actions. The shapes don't measure anyone's loss of weight.
Your whole body's response can't be judged from cell tests.
A 2025 paper examined blood fats and proteins in people [14]. Some had obesity; others had type 2 diabetes. At 8 and 12 mg, certain blood proteins fell. Those proteins affect how the body clears fat from blood.
Blood fats and a type of cholesterol fell too.
Researchers linked the changes with glucagon's action. Lower protein levels alone aren't a measure of better health. You can't judge benefits without lasting health findings.
Retatrutide dosage: what amounts belonged to studies?
Study amounts can look like choices for your own care. Phase 2 obesity work tested 1, 4, 8 and 12 mg [1]. The drug went into fat under skin in weekly shots. Phase 2 type 2 diabetes work tested 0.5-12 mg with gradual increases [2].
Those research amounts aren't an approved plan for you.
The early Phase 1b work also raised amounts gradually [4]. Smaller amounts included 0.5, 1.5 and 3 mg. A rising group followed steps written as 3/6/9/12 mg. The slashes list successive amounts, not amounts taken together.
Staff increased those amounts while checking patients' health.
Phase 1b found drug levels halved over a 6-day stretch [4]. Researchers measured drug in the liquid part of blood. That fall in levels helped explain shots each week.
You still don't have approved patient amounts or timing.
How to reconstitute retatrutide? Reconstitute means adding liquid to a powder to dissolve it. There's no approved home mixing method. Trial supplies come prepared and free from germs. The company supplies single-use pens or vials made under medicine rules.
Research sellers' products don't have the same assured checks. You can't infer a safe home mixture from trial supplies.
Retatrutide cost: can you know a prescription price?
You can't compare a prescription price that doesn't exist. Retatrutide has no approved product or approved price. If approval comes, the future price remains unknown.
You can't compare a retatrutide prescription price with what you pay now.
Some sellers offer products marked for research. Those products aren't equivalent to approved medicine. In 2025, the FDA sent over 50 warning letters to sellers [7].
Unchecked products can't provide a reliable prescription-price comparison.
No research-product prices are given here. A meaningful medicine comparison needs an approved retatrutide product first.